Evidence map›Paper›PMID 41628087›Full record

ArticleAnnals of nutrition & metabolism2026

Interrelationships between Sarcopenia, Bone Mass, and Metabolic Parameters in Pediatric Obesity.

Marcela Mikulska, Kamila Czepczor-Bernat, Katarzyna Sawielew, Patrycja Dolibog, Paweł T Dolibog, Paweł Matusik

Abstract read
In one paragraph

Article in Annals of nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marcela MikulskaDepartment of Pediatrics, Pediatric Obesity and Metabolic Bone Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland, marcela.mikulska@icloud.com.
Kamila Czepczor-BernatDepartment of Pediatrics, Pediatric Obesity and Metabolic Bone Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
Katarzyna SawielewDepartment of Pediatrics, Pediatric Obesity and Metabolic Bone Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
Patrycja DolibogDepartment of Medical Biophysics, Medical University of Silesia, Katowice, Poland.
Paweł T DolibogDepartment of Biophysics, Faculty of Medical Sciences, Medical University of Silesia, Zabrze, Poland.
Paweł MatusikDepartment of Pediatrics, Pediatric Obesity and Metabolic Bone Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<p>Introduction: Sarcopenic obesity (SO) is defined as co-existence of obesity and sarcopenia. The co-occurrence of sarcopenia and obesity might act synergistically and SO might have a greater effect on adverse health outcomes than sarcopenia or obesity alone. The term osteosarcopenic obesity was introduced recently to describe the impairment of bone, muscle, and fat tissues. This study aimed to evaluate cardiometabolic and bone parameters in relation with the presence of sarcopenia and their association with components of sarcopenia (muscle strength, muscle mass, and physical performance) in children and adolescents with obesity.

methodsA total of 95 children and adolescents with obesity (diagnosed with the use of International Obesity Task Force criteria) with a mean age of 12.7(±3) years participated in this study. Body composition was evaluated by bioelectrical impedance (BIA) and dual-energy X-ray absorptiometry (DXA). Grip strength and physical performance (six-minute walk test, timed up and go test) were evaluated. Blood pressure was measured and blood samples were taken. Sarcopenia was defined as co-occurrence of weak handgrip strength (≤10th centile) according to Dodds et al. [PLoS One. 2014;9(12):e113637] and low DXA-ASMM% (appendicular muscle mass/weight × 100%) (≤9nd centile) according to McCarthy et al. [Pediatr Obes. 2014;9(4):249-59].

resultsThe overall prevalence of sarcopenia was 17.89%. In comparison with patients without sarcopenia, those with sarcopenia had significantly higher high-density lipoprotein cholesterol (HDL-C) and significantly lower total body less head bone mineral content (BMC-TBLH) and total body less head bone mineral density (BMD-TBLH). Partial correlation analyses controlling for age and sex were performed. BIA-ASMM% and DXA-ASMM% were negatively correlated with insulin 0', homeostasis model assessment of insulin resistance (HOMA-IR) and diastolic blood pressure. DXA-ASMM% correlated negatively with total cholesterol. Handgrip strength was negatively correlated with total cholesterol, low-density lipoprotein (LDL), and HDL cholesterol. Maximal handgrip was positively correlated with bone parameters (BMC-TBLH, BMC-lumbar spine (LS), BMD-TBLH, and BMD-LS). The highest diagnostic value for detecting sarcopenia in children and adolescents with obesity was achieved by HDL-C (cut-off value >44.8 mg/dL), area under ROC curve (AUC) = 0.73).

conclusionMuscle mass and muscle strength were significantly associated with cardiometabolic parameters in children and adolescents with obesity. The best independent predictive risk factor for diagnosing sarcopenia in obese children and adolescents is HDL-C (cut-off value >44.8 mg/dL). The results of our study regarding bone parameters suggest the presence of osteosarcopenic obesity. </p>.

Indexed as

Bone DensityPediatric ObesitySarcopeniaAbsorptiometry, PhotonAdolescentBlood PressureBody CompositionBody Mass IndexChildCross-Sectional StudiesElectric ImpedanceFemaleHand StrengthHumansInsulin ResistanceMaleChildhood obesityMetabolic outcomesOsteosarcopenic obesitySarcopeniaSarcopenic obesity

Identifiers

PMID41628087
PMCPMC12965724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.